Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
1.435
-0.005 (-0.35%)
Mar 5, 2026, 10:37 AM EST - Market open
Marker Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Marker Therapeutics stock have an average target of 11.25, with a low estimate of 10 and a high estimate of 12.5. The average target predicts an increase of 683.97% from the current stock price of 1.44.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 8, 2025.
Analyst Ratings
The average analyst rating for Marker Therapeutics stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $10 | Strong Buy | Initiates | $10 | +596.86% | Dec 8, 2025 |
| WBB Securities | WBB Securities | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +771.08% | Apr 1, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +457.49% | Mar 5, 2025 |
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Maintains $11 → $19 | Strong Buy | Maintains | $11 → $19 | +1,224.04% | Oct 21, 2024 |
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +666.55% | Apr 30, 2024 |
Financial Forecast
Revenue This Year
3.16M
from 6.59M
Decreased by -52.03%
Revenue Next Year
2.75M
from 3.16M
Decreased by -12.90%
EPS This Year
-0.96
from -1.19
EPS Next Year
-1.47
from -0.96
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 4.1M | 6.1M | ||||
| Avg | 3.2M | 2.8M | ||||
| Low | 2.4M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -37.9% | 92.6% | ||||
| Avg | -52.0% | -12.9% | ||||
| Low | -64.3% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.97 | -0.64 | ||||
| Avg | -0.96 | -1.47 | ||||
| Low | -0.94 | -2.69 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.